Eupraxia Pharmaceuticals Inc. (EPRX)
NASDAQ: EPRX · Real-Time Price · USD
5.49
-0.05 (-0.90%)
At close: Jul 25, 2025, 4:00 PM
5.88
+0.39 (7.10%)
After-hours: Jul 25, 2025, 7:49 PM EDT

Company Description

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need.

The company’s proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need.

Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unmet medical needs and pain relief for knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery.

The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.

Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals logo
CountryCanada
Founded2011
IndustryBiotechnology
SectorHealthcare
Employees33
CEOJames Helliwell

Contact Details

Address:
2067 Cadboro Bay Road, Suite 201
Victoria, BC V8R 5G4
Canada
Phone250-590-3968
Websiteeupraxiapharma.com

Stock Details

Ticker SymbolEPRX
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001581178
ISIN NumberCA29842P1053
SIC Code2834

Key Executives

NamePosition
Dr. James A. Helliwell FRCPC, M.D.Chief Executive Officer and Director
Dr. Amanda Malone Ph.D.Chief Scientific Officer and Chief Operating Officer
Paul Anthony Brennan B.Sc., M.Sc.Chief Business Officer
Dr. Mark M. Kowalski M.D., Ph.D.Chief Medical Officer
Alexander John Rothwell Eng., M.B.A.Chief Financial Officer

Latest SEC Filings

DateTypeTitle
Jul 22, 20256-KReport of foreign issuer
Jul 8, 20256-KReport of foreign issuer
Jun 3, 20256-KReport of foreign issuer
Jun 2, 20256-KReport of foreign issuer
May 7, 20256-KReport of foreign issuer
May 6, 20256-KReport of foreign issuer
May 5, 20256-KReport of foreign issuer
Apr 24, 20256-KReport of foreign issuer
Mar 21, 20256-KReport of foreign issuer
Mar 20, 202540-FFiling